Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?

J Card Fail. 2024 Sep;30(9):1181-1182. doi: 10.1016/j.cardfail.2024.05.006. Epub 2024 Jun 4.

Authors

João Pedro Ferreira¹, Luís Mendonça², João Sérgio Neves²

Affiliations

¹ Faculty of Medicine of the University of Porto, Porto, Portugal. Electronic address: jpferreira@med.up.pt.
² Faculty of Medicine of the University of Porto, Porto, Portugal.

PMID: 38838981
DOI: 10.1016/j.cardfail.2024.05.006

No abstract available

Keywords: Semaglutide, SGLT2 inhibitor, type 2 diabetes; chronic kidney disease.

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptides* / adverse effects
Glucagon-Like Peptides* / therapeutic use
Humans
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
semaglutide
Glucagon-Like Peptides